Shiga, Japan

Jun Wada

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Morishita Jintan Co., Ltd.. Active years: 2013.


% Patents Active = 100.0



Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jun Wada - Innovator in Bifidobacterium Surface-Displayed Proteins

Introduction

Jun Wada is a notable inventor based in Shiga, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of innovative methods for protein expression.

Latest Patents

Wada holds a patent for a gene expressing a bifidobacterium surface-presented fusion protein. This invention provides a means of expressing and displaying a protein on the cell surface of bifidobacterium. The gene for expressing this protein links a gene coding for a GNB/LNB substrate-binding membrane protein and a gene coding for the target protein or peptide. This innovative approach allows transformed bifidobacterium to express the target protein or peptide on its surface. When the target protein or peptide is an antigen, the transformed bifidobacterium can serve as an effective oral vaccine.

Career Highlights

Wada is associated with Morishita Jintan Co., Ltd., where he continues to advance his research and development efforts. His work has the potential to impact the field of immunology and vaccine development significantly.

Collaborations

Wada collaborates with notable colleagues, including Toshiro Shirakawa and Sakura Yamamoto, who contribute to his research endeavors.

Conclusion

Jun Wada's innovative work in protein expression and vaccine development highlights his role as a key inventor in the biotechnology sector. His contributions are paving the way for advancements in oral vaccines and immunological research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…